Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 12;16(7):1244–1251. doi: 10.4103/1673-5374.301031

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2021 Neural Regeneration Research

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

PMC Copyright notice

Enhanced motor recovery with atomoxetine or fluoxetine treatment in grid-walking test.

(A, B) Following photothrombotic stroke mice treated with atomoxetine or fluoxetine exhibited dose-dependent improvement in affected forelimb motor function (i.e., decreased number of footfaults; n = 12 per group). Compared to the vehicle-treated group, mice treated with 1 mg/kg atomoxetine (^aP = 0.007) or 10 mg/kg fluoxetine (^fP = 0.011) showed statistically significantly improved motor function on day 42 after stroke (two-way repeated measures ANOVA followed by Dunnett’s multiple comparison). (C) No functional deficit was observed in the unaffected (i.e., ipsilateral) forepaw of mice in experimental groups (two-way repeated measures ANOVA followed by Dunnett’s multiple comparison, P > 0.05 for all within group and within day comparisons). Values are expressed as mean ± standard error. ANOVA: Analysis of variance. Atomo 0.3: 0.3 mg/kg atomoxetine; Atomo 1.0: 1.0 mg/kg atomoxetine; Fluox 3.0: 3 mg/kg fluoxetine; Fluox 10.0: 10 mg/kg fluoxetine.